0001209191-23-011263.txt : 20230221
0001209191-23-011263.hdr.sgml : 20230221
20230221170153
ACCESSION NUMBER: 0001209191-23-011263
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230217
FILED AS OF DATE: 20230221
DATE AS OF CHANGE: 20230221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: York Charles N II
CENTRAL INDEX KEY: 0001655962
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40431
FILM NUMBER: 23649247
MAIL ADDRESS:
STREET 1: 901 S. MOPAC EXPRESSWAY
STREET 2: BARTON OAKS PLAZA ONE, SUITE 250
CITY: AUSTIN
STATE: TX
ZIP: 78746
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001845337
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832415215
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY, SUITE 501
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 650 484-0899
MAIL ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY, SUITE 501
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC
DATE OF NAME CHANGE: 20210209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-17
0
0001845337
Day One Biopharmaceuticals, Inc.
DAWN
0001655962
York Charles N II
2000 SIERRA POINT PARKWAY, SUITE 501
BRISBANE
CA
94005
0
1
0
0
COO, CFO and Secretary
Common Stock
2023-02-17
4
S
0
9377
20.0267
D
262128
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Charles N. York II
2023-02-21